Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (44)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Martin, E. A.
Right arrow Articles by Smith, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, E. A.
Right arrow Articles by Smith, L. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 1061-1069, Copyright © 1998 by Oxford University Press

ARTICLES

Evaluation of tamoxifen and alpha-hydroxytamoxifen 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method

EA Martin, RT Heydon, K Brown, JE Brown, CK Lim, IN White and LL Smith
MRC Toxicology Unit, Leicester, UK. eam6@le.ac.uk

A novel HPLC system has been developed that has allowed the separation of tamoxifen DNA adducts formed in the livers of rats and mice treated with this drug. At least 13 different peaks have been separated from 32P-post-labelled DNA, with two major peaks jointly accounting for >60% of the total adducts formed by tamoxifen in the livers of treated rats and mice. This is a great improvement on the resolution obtained by thin layer chromatography, which separates the adducts into one main product consisting of a group of major adduct spots eluting together, plus several other minor spots. Identification of the nature of some of the peaks has been investigated. Comparisons of the products formed when alpha-acetoxytamoxifen is reacted with DNA in vitro with 32P-post- labelled liver DNA adducts from rats treated with tamoxifen or alpha- hydroxytamoxifen in vivo, appear to confirm that a major route of activation of tamoxifen in vivo is via alpha-hydroxylation. The resolving power of this HPLC system has further extended this result to show that six of the peaks, including the two major peaks, are formed by the reaction of an activated alpha-hydroxytamoxifen with DNA. Activation of 4-hydroxytamoxifen by the peroxidase/H2O2 system in vitro gives a more polar DNA adduct seen only at trace levels in liver DNA from tamoxifen-treated rats and mice.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. Liapis, K. I.E. McLuckie, P. D. Lewis, P. B. Farmer, and K. Brown
Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots
Nucleic Acids Res., October 1, 2008; 36(18): 5933 - 5945.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
Mutagenesis, March 1, 2005; 20(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier
Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days
Cancer Res., September 15, 2003; 63(18): 5999 - 6003.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Maiti and G. Chen
Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine
Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White
Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA
Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin
Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats
Carcinogenesis, April 1, 2001; 22(4): 553 - 557.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al.
Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide
Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen
Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips
Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction
Cancer Res., June 1, 2000; 60(11): 2887 - 2891.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Carthew, R. E. Edwards, B. M. Nolan, E. A. Martin, R. T. Heydon, I. N.H. White, and M. J. Tucker
Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
Carcinogenesis, April 1, 2000; 21(4): 793 - 797.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips, A. Hewer, M. N. Horton, K. J. Cole, P. L. Carmichael, W. Davis, and M. R. Osborne
N-Demethylation accompanies {alpha}-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Carcinogenesis, October 1, 1999; 20(10): 2003 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin
Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
I. N.H. White
The tamoxifen dilemma
Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Terashima, N. Suzuki, and S. Shibutani
Mutagenic Potential of {{alpha}}-(N2-Deoxyguanosinyl)tamoxifen Lesions, the Major DNA Adducts Detected in Endometrial Tissues of Patients Treated with Tamoxifen
Cancer Res., May 1, 1999; 59(9): 2091 - 2095.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, I. N.H. White, and B. K. Park
{alpha}-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro
Carcinogenesis, January 1, 1999; 20(1): 153 - 160.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.